BREAST CANCER

Findings from ongoing immunotherapy studies are expected to change the treatment paradigm in breast cancer as these agents become available to larger subsets of patients, according to Hope S. Rugo, MD, and Elizabeth A. Mittendorf, MD, PhD, who presented data at the 36th Annual Miami Breast Cancer Conference® hosted by Physicians’ Education Resource®, LLC.

In topline findings from the phase II DESTINY-BreastO1 study, [fam-] trastuzumab deruxtecan demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine.

The FDA has granted a fast track designation to a novel CCR5 antagonist, leronlimab (PRO 140), for use in combination with carboplatin to treat patients with CCR5-positive metastatic triple-negative breast cancer.

Ado-trastuzumab emtansine has been approved by the FDA for use as an adjuvant treatment option for patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab and chemotherapy.

A look back at all the FDA news that happened in the month of April 2019, including several new approvals, a priority review, breakthrough designation, and more.

John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has been launched by Roche to help identify&nbsp;<em>HER2</em> amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

A Case of HR+ Metastatic Breast Cancer

While predictive genetic testing is useful and even crucial for many populations, new medical advances are routinely overhyped in the media and misunderstood by consumers and providers alike.

HR+ Metastatic Breast Cancer

This article focuses specifically on the role of ovarian suppression in young premenopausal women. It reviews methods of ovarian suppression, provides evidence from recent pivotal clinical trials, outlines guidelines for its use, and discusses best practices and practical management applications.